Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Seqvera Ltd. OY manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This active matter is handled by 1 distinct examiner and 1 distinct art unit. This indicates that the company's current prosecution efforts are concentrated within a single technical specialty and a single administrative unit at the patent office.
The busiest examiner for this portfolio is LUO, JAMMY NMN, who is responsible for 1 busiest examiner pending action. This figure represents the entirety of the company's 1 pending office action workload. The prosecution of this Biotechnology & Pharmaceuticals portfolio is therefore focused on the specific requirements and feedback provided by this single examiner, with no other active cases to manage simultaneously.
The 1:1 ratio between the distinct examiner and the pending office action ensures a streamlined communication process for the company. However, the reliance on 1 distinct art unit means the portfolio's immediate progress is subject to the specific examination practices of that unit. With only 1 pending office action, the company's current success in the Biotechnology & Pharmaceuticals sector depends on the outcome of this single matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LUO, JAMMY NMN | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17875843 | MODEL-FREE TIME-INVARIANT EVALUATION OF TRANSPORT AND EFFICACY OF CHEMICALS AND DRUGS | LUO, JAMMY NMN | 9d |
| Art Unit | Apps |
|---|---|
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17875843 | MODEL-FREE TIME-INVARIANT EVALUATION OF TRANSPORT AND EFFICACY OF CHEMICALS AND DRUGS | LUO, JAMMY NMN | 1686 | §101§112 | Non-Final OA | 9d | Pending | Jul 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSeqvera Ltd. OY has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jammy Nmn Luo has the most, with 1 of Seqvera Ltd. OY's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
